<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01142219</url>
  </required_header>
  <id_info>
    <org_study_id>04-487 cep@hcpa.ufrgs.br</org_study_id>
    <nct_id>NCT01142219</nct_id>
  </id_info>
  <brief_title>L-Arginine and Sickle Cell Disease</brief_title>
  <official_title>A Randomized, Controlled, Double-blind Clinical Trial of L-arginine as Adjuvant Therapy for Sickle Cell Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fundo de Incentivo à Pesquisa do Hospital de Clinicas de Porto Alegre (FIPE)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Associação de Amigos da Hematologia (HEMOAMIGOS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ajinomoto Interamericana Indústria e Comércio Ltda. (donation of L-arginine)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      One of the main problems in sickle cell disease is the decreased bioavailability of nitric
      oxide and arginine. This study was designed to assess if treating sickle cell disease
      patients with L-arginine would improve pulmonary arterial pressure and other aspects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase III, randomized, double-blind, placebo-controlled clinical trial with sickle
      cell disease patients older than 1 year of age. The patients were randomly assigned to take
      0.1 g/kg/day of either L-arginine or placebo orally. Adverse events were monitored by a
      safety committee. The variables were assessed while patients were in remission, as part of
      their routine care: weight, blood pressure, full blood cell count, creatinine and dosage of
      methemoglobin at baseline and at each follow-up visit. Peripheral oxygen saturation (SpO2),
      fetal hemoglobin, lactate dehydrogenase and tricuspid regurgitant jet velocity were measured
      through transthoracic Doppler echocardiogram before and after treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tricuspid regurgitant jet velocity &gt;2.5 m/s</measure>
    <time_frame>6 months</time_frame>
    <description>Tricuspid regurgitant jet velocity was used to assess pulmonary arterial hypertension before and after treatment with L-arginine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lactate dehydrogenase levels</measure>
    <time_frame>6 months</time_frame>
    <description>The effect of L-argigine administration on hemolysis was assessed through the variation of serum levels of lactate dehydrogenase.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>L-arginine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.1g/kg/day for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-arginine</intervention_name>
    <description>L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.</description>
    <arm_group_label>L-arginine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Mannitol was administered orally at a dose of 01 g/kg/day for six months.</description>
    <arm_group_label>L-arginine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of sickle cell disease confirmed through hemoglobin electrophoresis

          -  Genotypes SS, SC and Sβ thalassemia

          -  Age &gt; 1 year

        Exclusion Criteria:

          -  Liver dysfunction (alanine aminotransferase ALT &gt; 3 times the normal levels

          -  Renal dysfunction (creatinine &gt; twice the normal levels)

          -  Increase in methemoglobin levels (&gt; 5 times the normal levels)

          -  History of recent stroke (&lt; 1 month) and priapism

          -  Pregnancy

          -  Allergy to L-arginine

          -  Use of sildenafil, calcium channel blockers, nitroglycerin or other nitrates
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2010</study_first_submitted>
  <study_first_submitted_qc>June 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2010</study_first_posted>
  <last_update_submitted>June 10, 2010</last_update_submitted>
  <last_update_submitted_qc>June 10, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2010</last_update_posted>
  <responsible_party>
    <name_title>Christina Matzenbacher Bittar</name_title>
    <organization>Hospital de Clínicas de Porto Alegre</organization>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>L-arginine</keyword>
  <keyword>hemolysis</keyword>
  <keyword>nitric oxide</keyword>
  <keyword>pulmonary arterial hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

